Float Short %

8.19

Margin Of Safety %

-12

Put/Call OI Ratio

0.44

EPS Next Q Diff

0.04

EPS Last/This Y

-0.25

EPS This/Next Y

0.34

Price

18.82

Target Price

Analyst Recom

Performance Q

34.52

Relative Volume

0.63

Beta

0.48

Ticker: ADMA

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	ADMA	19.79	0.34	3.99	69527
2025-12-10	ADMA	19.99	0.34	0.74	69520
2025-12-11	ADMA	20.39	0.34	0.66	69580
2025-12-12	ADMA	19.78	0.34	0.26	69829
2025-12-15	ADMA	19.75	0.34	3.55	69825
2025-12-16	ADMA	19.17	0.36	3.77	70916
2025-12-17	ADMA	18.83	0.47	2.95	76549
2025-12-18	ADMA	18.82	0.46	4.49	76747
2025-12-19	ADMA	19.59	0.45	0.40	76352
2025-12-22	ADMA	19.88	0.39	1.83	69498
2025-12-23	ADMA	19.5	0.40	0.31	70578
2025-12-26	ADMA	19.26	0.40	0.54	70989
2025-12-29	ADMA	19.1	0.40	0.52	71069
2025-12-30	ADMA	18.35	0.40	0.59	71159
2025-12-31	ADMA	18.26	0.40	5.81	70754
2026-01-02	ADMA	17.89	0.43	11.68	72398
2026-01-05	ADMA	18.03	0.44	0.65	72669
2026-01-06	ADMA	18.33	0.44	0.86	72941
2026-01-07	ADMA	18.81	0.44	0.47	73145
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	ADMA	19.80	43.4	-	0.59
2025-12-10	ADMA	19.80	43.4	-	0.59
2025-12-11	ADMA	20.38	43.4	-	0.59
2025-12-12	ADMA	19.77	43.4	-	0.59
2025-12-15	ADMA	19.73	43.4	-	0.59
2025-12-16	ADMA	19.73	47.1	-	0.60
2025-12-17	ADMA	18.84	47.1	-	0.60
2025-12-18	ADMA	18.82	47.1	-	0.60
2025-12-19	ADMA	19.58	47.1	-	0.60
2025-12-22	ADMA	19.86	47.1	-	0.60
2025-12-23	ADMA	19.49	47.1	-	0.60
2025-12-26	ADMA	19.27	47.1	-	0.60
2025-12-29	ADMA	19.11	47.1	-	0.60
2025-12-30	ADMA	18.34	47.1	-	0.60
2025-12-31	ADMA	18.25	47.1	-	0.60
2026-01-02	ADMA	17.89	47.1	-	0.60
2026-01-05	ADMA	18.03	47.1	-	0.60
2026-01-06	ADMA	18.33	47.1	-	0.60
2026-01-07	ADMA	18.82	47.1	-	0.60
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	ADMA	-6.71	3.23	8.10
2025-12-10	ADMA	-6.71	3.23	8.07
2025-12-11	ADMA	-6.60	3.23	8.07
2025-12-12	ADMA	-6.40	3.23	8.07
2025-12-15	ADMA	-6.40	3.21	8.07
2025-12-16	ADMA	-6.38	3.21	8.07
2025-12-17	ADMA	-1.78	3.21	8.07
2025-12-18	ADMA	-1.78	3.21	8.07
2025-12-19	ADMA	-1.53	3.21	8.07
2025-12-22	ADMA	-1.53	3.21	8.07
2025-12-23	ADMA	-1.53	3.21	8.07
2025-12-26	ADMA	-1.53	3.21	8.19
2025-12-29	ADMA	-1.53	3.21	8.19
2025-12-30	ADMA	-1.53	3.21	8.19
2025-12-31	ADMA	-1.53	3.21	8.19
2026-01-02	ADMA	-1.53	3.21	8.19
2026-01-05	ADMA	-1.53	3.21	8.19
2026-01-06	ADMA	-1.53	3.21	8.19
2026-01-07	ADMA	-1.53	3.21	8.19
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

0.16

Avg. EPS Est. Current Quarter

0.2

Avg. EPS Est. Next Quarter

0.2

Insider Transactions

-1.53

Institutional Transactions

3.21

Beta

0.48

Average Sales Estimate Current Quarter

139

Average Sales Estimate Next Quarter

145

Fair Value

16.59

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

26.7

Max Drawdown 5-Year %

-63.1

Target Price

P/E

22.1

Forward P/E

21.39

PEG

0.62

P/S

9.17

P/B

10.4

P/Free Cash Flow

109.97

EPS

0.85

Average EPS Est. Cur. Y

0.6

EPS Next Y. (Est.)

0.94

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

42.87

Relative Volume

0.63

Return on Equity vs Sector %

21.5

Return on Equity vs Industry %

36.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ADMA Biologics Inc

Sector: Healthcare

Industry: Biotechnology

Employees: 677

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

stock quote shares ADMA – Adma Biologics Inc Stock Price stock today

news today ADMA – Adma Biologics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch ADMA – Adma Biologics Inc yahoo finance google finance

stock history ADMA – Adma Biologics Inc invest stock market

stock prices ADMA premarket after hours

ticker ADMA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ADMA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y